IRD Opus Genetics, Inc.
Price Chart
Executive Summary
Opus Genetics filed an S-3 shelf registration to register 7,374,632 shares of common stock for resale by selling stockholders, representing shares issuable upon conversion of Series B Preferred Stock issued in a private placement. The company received $25 million in net proceeds from the private placement, which will be used for clinical programs and general corporate purposes. The registration satisfies a contractual obligation and does not raise new capital for the company.
Actionable Insight
Monitor for potential share sales by the selling stockholders, which could create downward pressure on the stock price. The $25 million in funding provides runway for clinical development, but watch for future dilutive offerings if additional capital is needed.
Key Facts
- S-3 filing registers 7,374,632 shares for resale by selling stockholders
- Shares are issuable upon conversion of Series B Preferred Stock from a private placement
- Company received $25 million in net proceeds from the private placement
- Proceeds will be used to advance gene therapy clinical programs and for working capital
- Company will not receive any proceeds from the resale of shares by selling stockholders
- Registration satisfies a contractual obligation under a registration rights agreement
Financial Impact
The registration itself has no direct financial impact as the company won't receive proceeds from share resales. However, the $25 million from the private placement provides funding for clinical programs.
Risk Factors
- Potential share price pressure from resale of registered shares
- Future dilution if additional capital is raised through equity offerings
- Clinical trial risks for gene therapy programs
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001140361-26-009408 |
| Document: ny20067725x1_ex107.htm | 0001140361-26-009408 |
| Document: ny20067725x1_ex23-1.htm | 0001140361-26-009408 |
| Document: 0001140361-26-009408-index-headers.html | 0001140361-26-009408 |
| Document: 0001140361-26-009408-index.html | 0001140361-26-009408 |
| Document: 0001140361-26-009408.txt | 0001140361-26-009408 |
| CONTEXT: 10-Q (2025-11-12) | 0001140361-25-041547 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
S-3
| $4.61 awaiting T+5 | awaiting T+5 | — | $4.04 (+12.36%) |
|
May 12, 2026
4w ago
|
8-K
| $5.18 $4.44 | ▼ −14.29% | ▼ −14.36% | $4.04 (−22.01%) |
|
May 12, 2026
4w ago
|
Press Release
| $5.18 $4.44 | ▲ +14.29% | ▲ +14.36% | $4.04 (+22.01%) |
|
May 7, 2026
5w ago
|
Press Release
| $4.99 $4.97 | ▼ −0.40% | ▼ −1.86% | $4.04 (−19.04%) |
|
Apr 24, 2026
7w ago
|
8-K
| $5.12 $5.22 | ▲ +1.95% | ▲ +1.55% | $4.04 (−21.09%) |
|
Apr 23, 2026
7w ago
|
EFFECT
| $5.21 $4.67 | ▼ −10.36% | ▼ −11.84% | $4.04 (−22.46%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $5.21 $4.67 | ▼ −10.36% | ▼ −11.84% | $4.04 (−22.46%) |
|
Apr 10, 2026
9w ago
|
Press Release
| $5.36 $5.75 | ▲ +7.28% | ▲ +2.77% | $4.04 (−24.63%) |
|
Apr 7, 2026
9w ago
|
8-K
| $4.92 $5.55 | ▲ +12.80% | ▲ +7.48% | $4.04 (−17.89%) |
|
Mar 16, 2026
12w ago
|
Insider Cluster
| $5.19 $4.59 | ▼ −11.56% | ▼ −9.52% | $4.04 (−22.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access